We would be surprised if so Blueprint Medicines Corporation (NASDAQ: BPMC) shareholders are unaware that R&D president Fouad Namouni recently sold $234,000 worth of stock at $67.30 per share. That sale was his 23% of their holding, so we frown.
Blueprint Insider Trading of Drugs in the Last Year
The largest single insider sale in the past 12 months was when Executive Chairman Jeffrey Albers sold $746,000 worth of stock at $60.28 per share. So we know that the insider sold the stock at around the current price of US$59.00. We usually don’t want to see insider sales, but the lower the sale price, the more interest we have. This sale was near current prices, so it’s not a big concern, but it doesn’t bode well.
Overall, Blueprint Medicines insiders sold more than they bought last year. The chart below shows insider trading (by company and individual) over the past year. Clicking on the chart will show you all individual deals, such as stock, individual, and date.
For those who like to search investment win this freedom A list of growing companies that recently made insider acquisitions could be just the ticket.
Insider Ownership of Blueprint Medicines
I like to look at how many shares an insider owns in a company to inform my view of how well insiders and insiders match up. High insider ownership often leads company management to pay more attention to the interests of shareholders. Blueprint Medicines insiders own shares worth approximately US$31 million. This equates to his 0.9% of the company. Certainly we’ve seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest coordination between insiders and other shareholders.
So what does this data tell us about Blueprint Medicines Insider?
Insiders recently sold, but did not buy, Blueprint Medicines shares. The long-term outlook doesn’t make us feel so positive, despite some insider purchases. Please be careful before buying.So while these insider trading can help make the paper on the stock, it’s also worth knowing the risks facing this company. two warning signs I think you should know.
However, please note the following: Blueprint Medicines may not be the best stock to buy. Now take a look at this freedom A list of interesting companies with high ROE and low debt.
For the purposes of this article, an insider is an individual who reports a transaction to the relevant regulatory body. Currently, we consider open market transactions and private disposals, but not derivative transactions.
Do you have feedback on this article? What interests you? contact directly with us. Or send an email to our editorial team (at) Simplywallst.com.
This article by Simply Wall St is general in nature. We provide comments based on historical data and analyst projections using only unbiased methodologies and our articles are not intended as financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. We aim to deliver long-term focused analysis based on fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Is not …
Valuation is complicated, but we’re here to help make it simple.
find out if blueprint potion You may be overestimated or underestimated by checking out our comprehensive analysis including: Fair value estimates, risks and warnings, dividends, insider trading and financial health.
